About us Services Careers Contact us Privacy Coripharma’s Teriflunomide dossier available and ready for submission 21. Jul 2021 CORIPHARMA has completed its development of Teriflunomide 14mg tablets. The multiple sclerosis treatment is currently sold under the brand name Aubagio® by the originator company Sanofi. The new dossier is ready for submission, with DCP slots secured for August 2021 when data exclusivity expires, paving the way for an immediate first wave launch to coincide with patent expiry. Teriflunomide is the fourth dossier to be developed by CORIPHARMA and forms part of a fast-growing portfolio of products available for out-licensing. An additional 13 dossiers are currently under development with many scheduled for completion during next year. CORIPHARMA’S business development team is available to discuss out-licensing opportunities with partners in all markets. Please contact us to find out more. info@coripharma.is | +354 4206700 | www.coripharma.is Coripharma’s experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies requiring high quality products from a reliable European supplier. Located in Iceland, within the Schengen Area and the EEA, our modern manufacturing site is equipped to produce 1.2 billion tablets/capsules per annum. When you browse on this site, cookies collect data to enhance your experience. Visit our privacy policy (updated 15 APR 2019) and consent tool to learn more, and make choices about the data used. By clicking "Accept" or by continuing to use the site, you agree to this use of cookies and data. Privacy policy Consent tool Accept About us Services Careers Contact us Privacy Coripharma Reykjavikurvegur 78 - 80 220 Hafnarfjordur, Iceland Email info@coripharma.is Phone +354 4206700